Yousif Capital Management LLC Sells 2,979 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Yousif Capital Management LLC cut its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 61,942 shares of the company’s stock after selling 2,979 shares during the period. Yousif Capital Management LLC’s holdings in Option Care Health were worth $1,437,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of OPCH. FMR LLC boosted its position in Option Care Health by 134.0% during the 3rd quarter. FMR LLC now owns 7,516,448 shares of the company’s stock valued at $235,265,000 after acquiring an additional 4,304,896 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Option Care Health by 4,432.8% during the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock worth $50,756,000 after purchasing an additional 1,585,818 shares during the last quarter. Wellington Management Group LLP boosted its position in Option Care Health by 15.5% during the third quarter. Wellington Management Group LLP now owns 9,924,915 shares of the company’s stock valued at $310,650,000 after purchasing an additional 1,328,326 shares in the last quarter. Geneva Capital Management LLC bought a new stake in Option Care Health during the third quarter valued at about $24,679,000. Finally, Westfield Capital Management Co. LP grew its stake in Option Care Health by 10.2% in the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after purchasing an additional 599,589 shares during the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Price Performance

Shares of OPCH opened at $31.86 on Thursday. The firm has a market capitalization of $5.42 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 2.19 and a beta of 1.35. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The company’s fifty day moving average price is $26.34 and its 200-day moving average price is $27.88. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.63.

Wall Street Analyst Weigh In

OPCH has been the topic of a number of recent analyst reports. UBS Group assumed coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. raised their target price on shares of Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Jefferies Financial Group raised shares of Option Care Health from a “hold” rating to a “buy” rating and lifted their price target for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. Truist Financial decreased their price objective on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 target price (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Option Care Health has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.